⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
JAGX News
Jaguar Health, Inc.
Presentation at ESPGHAN 2026 Describes Additional Groundbreaking Results of Evaluation of Jaguar Health's Crofelemer as Adjunctive Oral Therapy for the Treatment of Pediatric Intestinal Failure (IF)
accessnewswire.com
JAGX
Form 8-K
sec.gov
JAGX
Jaguar Health Announces Conversion of Series O Convertible Preferred Stock Issued as Recent One-time Stock Dividend
accessnewswire.com
JAGX
Jaguar Health Completes Submission of New Animal Drug Application for Full FDA Approval of Crofelemer for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs
accessnewswire.com
JAGX
Form 8-K/A
sec.gov
JAGX
Form 8-K
sec.gov
JAGX
Jaguar Health Announces Plan to Explore Strategic Alternatives Aligned with Targeted NDA Filing for Rare Disease Intestinal Failure Program
accessnewswire.com
JAGX
Form 8-K
sec.gov
JAGX
Red Light Holland Reports Positive Preclinical Study Results for Coca in Weight Gain Prevention Post GLP-1 from Magdalena Biosciences, the Joint Venture Held Through Its Wholly Owned Subsidiary, Filament Health Ready to Announce with Confidence?
newsfilecorp.com
JAGX
Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, Announces Positive Results of Preclinical Study of Coca for Weight Gain Prevention
accessnewswire.com
JAGX